Advanced searches left 3/3

Major Depressive Disorder - Springer Nature

Summarized by Plex Scholar
Last Updated: 21 July 2022

* If you want to update the article please login/register

Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents

In half of the patients, bipolar disorder begins in childhood or adolescence. Depressive episodes are usually present in early stages of BD, making it difficult to discern from major depressive disorder. Objective biomarkers for distinguishing BD from MDD in adolescent patients are limited. Basic demographic data and the results of the first blood examination that was performed after the admission of BD and MDD patients to the psychiatry unit of the BD and MDD inpatients during 2009-2013-2018. Forward-Stepwise Selecting binary logistic regression was used to build predictive models for the complete sample and subgroups by gender. This review reveals that publicly available reports of common laboratory examination may be helpful in determining BD form MDD in adolescents. With strong diagnostic accuracy and external validation, the complete regression equation could be used to tailored clinical inferences on adolescent BD patients.

Source link: https://doi.org/10.1007/s00406-021-01321-4


Childhood adversity, adulthood adversity and suicidal ideation in Chinese patients with major depressive disorder: in line with stress sensitization

However, the effect of stress sensitization on suicidality in patients with a severe depressive disorder has not been explored before. Patients with suicidal ideation were more likely to report CA or AA than patients without suicidal ideation. Patients who had two waves of adversity were associated with higher rates of suicidal ideation, but no CA nor AA alone was connected with suicidal thoughttion. This research is the first to support the argument that stress sensitization on suicidal ideation in patients with MDD.

Source link: https://doi.org/10.1007/s00406-021-01375-4


Shared and distinct reward neural mechanisms among patients with schizophrenia, major depressive disorder, and bipolar disorder: an effort-based functional imaging study

Patients with higher reward magnitudes than HC, SCZ patients had greater functional connectivity between the right and the left amygdala, the left hippocampus, and the left putamen. With the increase of reward magnitude, MDD patients showed an enhanced activation compared to HC in the right superior temporal gyrus. The relationship between the caudate and the right cingulate gyrus, the left postcentral gyrus, and the left inferior parietal lobule with increase in reward magnitude was smaller than that found in HC. The degree of activation in the left precuneus was elevated in BD patients, but it was decreased in the left dorsolateral prefrontal cortex as a result of reduced reward quality relative to HC.

Source link: https://doi.org/10.1007/s00406-021-01376-3


Association between thyroid function and comorbid anxiety in first-episode and drug naïve patients with major depressive disorder

This study was designed to evaluate thyroid function in a large population of first-efe MDD patients with and without anxiety. Compared to MDD patients without anxiety, MDD patients with anxiety were more likely to have more suicide attempts and psychotic signs, as well as higher serum TSH, TPOAb, and TGAb. Patients with comorbid and without anxiety were 1. 657 for elevated TSH levels, 1. 943 for elevated TGAb levels, and 2. 448 for elevated TPOAb levels. Conclusions Our findings show that comorbid anxiety in FEDN MDD patients is positively associated with elevated TSH and TGAb levels, which may be useful biomarkers of comorbid anxiety in MDD patients. In MDD patients, chronic dysfunctional thyroid function could be helpful for comorbid anxiety.

Source link: https://doi.org/10.1007/s00406-022-01457-x


Distinct proteomic profiles in prefrontal subareas of elderly major depressive disorder and bipolar disorder patients

For the first time, we looked at the proteomic results both in the dorsolateral prefrontal cortex and anterior cingulate cortex of patients with significant depressive disorder and bipolar disorder patients. Over 3000 proteins were precisely measured, with more than 100 protein expressions showing significant improvements in these two brain regions of MDD and BD patients as compared to their respective controls. In the ACC of MDD, the most notable improvement we found in MDD's DLPFC was u2018suppressed tissue remodeling and reduced immune response;u2019suppressed neural regeneration and reduced neuronal projections were discernible; and in the DLPFC of BD it was u2018suppressed tissue remodeling and reduced neuronal growth. In summary, there are evident proteomic shifts in various brain regions of the same mood disorder, as well as in the same brain area between MDD and BD patients, which raises the distinct pathogeneses and thus treatment goals.

Source link: https://doi.org/10.1038/s41398-022-02040-7


Subjective well-being’s alterations as risk factors for major depressive disorder during the perimenopause onset: an analytical cross-sectional study amongst Mexican women residing in Guadalajara, Jalisco

Background Anthronism Weakness can be defined as a self-report assessment that represents the achievement and emotional wellbeing of a number of socioeconomic and emotional measurements. Despite increasing prevalence of depressive disorders in women's life stages, such as the onset of perimenopause, this association has not been studied at womenu2019s reproductive age, indicating that major depressive disorder could be risk factors for significant depressive disorder. The purpose of this research was to determine whether SWB's changes determine MDD during the perimenopause, determining MDD during the perimenopause. Methods An analytic cross-sectional research was conducted in 252 Mexican women with perimenopause u2019s age range and menopausal symptoms, which were treated on Medical Units of Jalisco's 13th Health-Region. Conclusions By aOR -Which were higher than international research findings, determining that SWB's changes are RF for depressive symptomatology was found to be RF for depressive symptomatology is the main aim of the study.

Source link: https://doi.org/10.1186/s12905-022-01848-1


Major depressive disorders increase the susceptibility to self-reported infections in two German cohort studies

Methods We used results from the BiDirect and the HaBIDS cohort studies to determine MDD's effect on self-reported infections, which were determined with identical infection susceptibility questionnaires in both studies. To determine if there was a dose-related relationship between depressive symptoms and self-reported infections, we used the Center for Epidemiologic Studies Depression Scale. After adjusting for confounders identified by a targeted acyclic graph method, MDD patients with MDD diagnosis had a higher risk of lower respiratory tract infections, intestinal infections, and fever. Conclusion We found elevated risks of mild infections in patients with MDD diagnosis as a result of a dose-u2013response relationship between depressive symptoms severity and infection frequency in patients with MDD diagnosis, as well as a dose-response relationship. Because the effect sizes in our study are similar to those of patients with cardiovascular and metabolic disease for which the respective vaccinations are recommended, we recommend vaccination against influenza and S. pneumoniae to MDD patients.

Source link: https://doi.org/10.1007/s00127-022-02328-5


Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017

According to severity, the International Classification of Diseases assigns a diagnosis of major depressive disorder. The aim of this study was to determine the use of psychotropic drugs based on the severity of MDD in psychiatric inpatients. According to the severity of MDD, drug use results from the program "u201cDrug Safety in Psychiatryu201d" were analyzed. In participating hospitals, 43,868 psychiatric inpatients with MDD were treated from 2001 to 2017. Select serotonin reuptake inhibitors and mirtazapine were more commonly used with selective serotonin reuptake inhibitors and mirtazapine than placebo, and less often with specific serotonin reuptake inhibitors. The number of psychotropic drugs used increased with increasing severity of MDDu2014patients with psychotic MDD had the highest usage of psychotropic drugs. ADD monotherapy was also present in patients with non-severe MDD, to a lesser degree. The results reveal substantial differences between guideline recommendations and real-life drug use, implying that policies can insufficiently reflect clinical needs within the psychiatric inpatient setting.

Source link: https://doi.org/10.1007/s00702-022-02504-6


A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population

In pharmacological experiments among healthy subjects and patients with PTSD or depression, we wanted to investigate the cognitive effects of subanesthetic doses of intravenous ketamine in subanesthetic doses of intravenous ketamine. We didn't find any studies that proved the use of ketamine only in combination with other medications or psychotherapy, or ones investigating emotion-laden cognitive functions. In comparison to the immediate cognitive dysfunction observed in healthy patients, ketamine therapy among patients with depression and possibly PTSD does not cause significant impairment of cognitive function in the short run. In executive functions, the potential procognitive benefits of ketamine are becoming more apparent, according to the putative molecular, cellular, and synaptic mechanisms of the drug's therapeutic function. Improved cognition by ketamine may be able to promote psychotherapy services for PTSD and depression.

Source link: https://doi.org/10.1007/s40261-022-01169-z


Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis

Background: Major depressive disorder, a common mental health disorder, can be difficult to treat. Objectivise We aimed to identify treatment patterns within and across multiple major depressive episodes in patients receiving treatment for significant depressive disorder. Methods Adults with newly diagnosed major depressive disorder and one or two major depressive episodes were discovered using the IBMu00ae Commercial Database, as well as one or two other significant depressive episodes. Antidepressant, atypical antipsychotic, or mood stabilizer regimens as monotherapy or adjunctive therapy were characterized by lines of therapy and major depressive episodes. About 19% of patients treated with atypical antipsychotic-adjunctive therapy stopped therapy after 42 percent of monotherapy-treated patients. Patients who received an adjunctive atypical antipsychotic were on average their third line of therapy and nearly 400 days after the first antidepressant therapy was administered. Conclusions Many patients maintained monotherapy major depressive disorder therapy regimens and underwent multiple treatment changes in this report, despite several treatment changes.

Source link: https://doi.org/10.1007/s40801-022-00316-4

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions